In a review of 170 AML patients treated at Mayo Clinic with HMA/VEN 20%(!) had a cardiac event, the majority occurred during cycle 1. The most common event was a decrease in the left ventricular ejection fraction. As HMA/VEN use continues to increase in popularity it will be important to keep an eye out for cardiac toxicity.
Note: The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision-making to the specific patient…
in anxiety in children and adolescents with chronic pain has not yet been examined. This study sought to expand our understanding of the associations between…
AI-based cancer diagnostic tools have fit rather seamlessly into clinical practice. They have also hinted at the potential for AI to benefit patients in other…
Learn how the Deloitte Health Equity Institute is translating purpose into action to advance health equity.
Moderna and OpenAI partner to accelerate the development of life-saving treatments.
Physicians, researchers, CEOs, reporters, and more gathered in downtown Boston Wednesday night to celebrate STAT’s 2024 STATUS List, which features 50
This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered…
